Immune checkpoint inhibitors (ICIs)-associated pancreatitis is a rare gastrointestinal adverse reaction of ICIs. At present, its pathogenesis is still unclear, and it is speculated that it may be related to the non-specific inflammatory T cell-mediated immune response triggered by ICIs. ICIs combination therapy, melanoma, individuals under 65 years old, and a history of pancreatitis are all risk factors. ICIs-associated pancreatitis may present with or without symptomatic elevation of pancreatic enzymes, and its diagnosis depends on medical history, laboratory evaluation and imaging examinations. ICIs-associated pancreatitis can be managed in a similar manner to classical acute pancreatitis, with treatment primarily consisting of fluid resuscitation and pain control, as well as the prevention and treatment of complications. Glucocorticoids are the cornerstone of the treatment of moderate and severe ICIs-associated pancreatitis. And the application of traditional immunosuppressants and biologics still needs further development.